Metabolic Syndrome and Risk of Breast Cancer by Molecular Subtype: Analysis of the MEND Study

doi:10.1016/j.clbc.2021.11.004

Metabolic Syndrome and Risk of Breast Cancer by Molecular Subtype: Analysis of the MEND Study

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Background: Metabolic syndrome (MetS) is characterized by a cluster of biological irregularities. The purpose of this analysis was to examine the association of MetS with BC among Nigerian women, and for the first time evaluate this association by molecular subtype. Materials and Methods: MetS was defined as having at least 3 out of 5 of: high blood pressure (≥ 130/85 mm Hg), reduced HDL (< 50 mg/dL), elevated triglyceride (> 150 mg/dL), high waist circumference (≥ 80 cm), and prior diagnosis of diabetes or elevated fasting glucose level (≥ 100 mg/dL). Among 296 newly diagnosed BC cases and 259 healthy controls, multivariable logistic regression models were utilized to estimate adjusted odds ratios (aOR) and 95% confidence intervals (95% CI) for the association between MetS and BC overall. Multinomial logistic regression models were used to evaluate each molecular subtype (Luminal A, Luminal B, HER2-enriched and triple-negative or TNBC). Results: After adjusting for age, socio-demographic and reproductive risk factors, there was a positive association between MetS and BC (aOR: 1.84, 95% CI: 1.07, 3.16). In stratified analyses, MetS was associated with BC regardless of BMI status; however, the estimate was significant only among normal weight women (aOR: 3.85; 95% CI: 1.25, 11.90). MetS was significantly associated with TNBC subtype (aOR: 4.37, 95% CI: 1.67, 11.44); associations for other molecular subtypes were not statistically significant. Conclusion: MetS appears to be a robust risk factor for BC, particularly for TNBC. Public health and clinical interventions can provide substantial benefits in reducing the burden of MetS and preventing BC among Nigerian women.

Original language	English
Pages (from-to)	e463-e472
Journal	Clinical Breast Cancer
Volume	22
Issue number	4
DOIs	https://doi.org/10.1016/j.clbc.2021.11.004
State	Published - Jun 2022

Bibliographical note

Publisher Copyright:
© 2021 The Author(s)

Funding

The authors acknowledge the role of the H3Africa Consortium in making this research possible through the sharing of data. The National Institutes of Health (USA) and Wellcome Trust (UK) have provided the core funding for the H3Africa Consortium. The authors thank the many MEND investigators who contributed substantially to the inception and design of the study, and the patients and families who participated in the MEND study for their vital contribution in advancing the science of cancer in Nigeria and globally. The authors acknowledge the important contribution of the MEND research nurses: Cordelia Ibeneme, Peju Olabanji, Rebecca Israel, Esther Akinwale, Deborah Awodeyi, and Shukurat Oduola. This work was supported by grants from the National Institutes of Health, National Cancer Institute, Fogarty International Center: K01TW010271, T.A. and NIH 1P30DK124723-01. The views expressed in this paper do not represent the views of the National Institutes of Health, H3Africa Consortium, or their funders. The authors acknowledge the role of the H3Africa Consortium in making this research possible through the sharing of data. The National Institutes of Health (USA) and Wellcome Trust (UK) have provided the core funding for the H3Africa Consortium. The authors thank the many MEND investigators who contributed substantially to the inception and design of the study, and the patients and families who participated in the MEND study for their vital contribution in advancing the science of cancer in Nigeria and globally. The authors acknowledge the important contribution of the MEND research nurses: Cordelia Ibeneme, Peju Olabanji, Rebecca Israel, Esther Akinwale, Deborah Awodeyi, and Shukurat Oduola. This work was supported by grants from the National Institutes of Health , National Cancer Institute , Fogarty International Center : K01TW010271 , T.A. and NIH 1P30DK124723-01 . The views expressed in this paper do not represent the views of the National Institutes of Health, H3Africa Consortium, or their funders.

Funders	Funder number
Mine Environment Neutral Drainage (MEND)
National Institutes of Health (NIH)	1P30DK124723-01
National Childhood Cancer Registry – National Cancer Institute
Fogarty International Center	K01TW010271
Wellcome Trust

Keywords

Cholesterol
Diabetes
Hypertension
Nigeria
Triple-negative breast cancer

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clbc.2021.11.004

Cite this

@article{7c99af3a76894a37beebbf6c3203a6ea,

title = "Metabolic Syndrome and Risk of Breast Cancer by Molecular Subtype: Analysis of the MEND Study",

abstract = "Background: Metabolic syndrome (MetS) is characterized by a cluster of biological irregularities. The purpose of this analysis was to examine the association of MetS with BC among Nigerian women, and for the first time evaluate this association by molecular subtype. Materials and Methods: MetS was defined as having at least 3 out of 5 of: high blood pressure (≥ 130/85 mm Hg), reduced HDL (< 50 mg/dL), elevated triglyceride (> 150 mg/dL), high waist circumference (≥ 80 cm), and prior diagnosis of diabetes or elevated fasting glucose level (≥ 100 mg/dL). Among 296 newly diagnosed BC cases and 259 healthy controls, multivariable logistic regression models were utilized to estimate adjusted odds ratios (aOR) and 95% confidence intervals (95% CI) for the association between MetS and BC overall. Multinomial logistic regression models were used to evaluate each molecular subtype (Luminal A, Luminal B, HER2-enriched and triple-negative or TNBC). Results: After adjusting for age, socio-demographic and reproductive risk factors, there was a positive association between MetS and BC (aOR: 1.84, 95% CI: 1.07, 3.16). In stratified analyses, MetS was associated with BC regardless of BMI status; however, the estimate was significant only among normal weight women (aOR: 3.85; 95% CI: 1.25, 11.90). MetS was significantly associated with TNBC subtype (aOR: 4.37, 95% CI: 1.67, 11.44); associations for other molecular subtypes were not statistically significant. Conclusion: MetS appears to be a robust risk factor for BC, particularly for TNBC. Public health and clinical interventions can provide substantial benefits in reducing the burden of MetS and preventing BC among Nigerian women.",

keywords = "Cholesterol, Diabetes, Hypertension, Nigeria, Triple-negative breast cancer",

author = "Tomi Akinyemiju and Taofik Oyekunle and Omolola Salako and Anjali Gupta and Olusegun Alatise and Gabriel Ogun and Adewale Adeniyi and April Deveaux and Allison Hall and Omobolaji Ayandipo and Thomas Olajide and Olalekan Olasehinde and Olukayode Arowolo and Adewale Adisa and Oludolapo Afuwape and Aralola Olusanya and Aderemi Adegoke and Tollefsbol, {Trygve O.} and Donna Arnett and Muehlbauer, {Michael J.} and Newgard, {Christopher B.} and Adetola Daramola",

note = "Publisher Copyright: {\textcopyright} 2021 The Author(s)",

year = "2022",

month = jun,

doi = "10.1016/j.clbc.2021.11.004",

language = "English",

volume = "22",

pages = "e463--e472",

number = "4",

}

TY - JOUR

T1 - Metabolic Syndrome and Risk of Breast Cancer by Molecular Subtype

T2 - Analysis of the MEND Study

AU - Akinyemiju, Tomi

AU - Oyekunle, Taofik

AU - Salako, Omolola

AU - Gupta, Anjali

AU - Alatise, Olusegun

AU - Ogun, Gabriel

AU - Adeniyi, Adewale

AU - Deveaux, April

AU - Hall, Allison

AU - Ayandipo, Omobolaji

AU - Olajide, Thomas

AU - Olasehinde, Olalekan

AU - Arowolo, Olukayode

AU - Adisa, Adewale

AU - Afuwape, Oludolapo

AU - Olusanya, Aralola

AU - Adegoke, Aderemi

AU - Tollefsbol, Trygve O.

AU - Arnett, Donna

AU - Muehlbauer, Michael J.

AU - Newgard, Christopher B.

AU - Daramola, Adetola

PY - 2022/6

Y1 - 2022/6

N2 - Background: Metabolic syndrome (MetS) is characterized by a cluster of biological irregularities. The purpose of this analysis was to examine the association of MetS with BC among Nigerian women, and for the first time evaluate this association by molecular subtype. Materials and Methods: MetS was defined as having at least 3 out of 5 of: high blood pressure (≥ 130/85 mm Hg), reduced HDL (< 50 mg/dL), elevated triglyceride (> 150 mg/dL), high waist circumference (≥ 80 cm), and prior diagnosis of diabetes or elevated fasting glucose level (≥ 100 mg/dL). Among 296 newly diagnosed BC cases and 259 healthy controls, multivariable logistic regression models were utilized to estimate adjusted odds ratios (aOR) and 95% confidence intervals (95% CI) for the association between MetS and BC overall. Multinomial logistic regression models were used to evaluate each molecular subtype (Luminal A, Luminal B, HER2-enriched and triple-negative or TNBC). Results: After adjusting for age, socio-demographic and reproductive risk factors, there was a positive association between MetS and BC (aOR: 1.84, 95% CI: 1.07, 3.16). In stratified analyses, MetS was associated with BC regardless of BMI status; however, the estimate was significant only among normal weight women (aOR: 3.85; 95% CI: 1.25, 11.90). MetS was significantly associated with TNBC subtype (aOR: 4.37, 95% CI: 1.67, 11.44); associations for other molecular subtypes were not statistically significant. Conclusion: MetS appears to be a robust risk factor for BC, particularly for TNBC. Public health and clinical interventions can provide substantial benefits in reducing the burden of MetS and preventing BC among Nigerian women.

AB - Background: Metabolic syndrome (MetS) is characterized by a cluster of biological irregularities. The purpose of this analysis was to examine the association of MetS with BC among Nigerian women, and for the first time evaluate this association by molecular subtype. Materials and Methods: MetS was defined as having at least 3 out of 5 of: high blood pressure (≥ 130/85 mm Hg), reduced HDL (< 50 mg/dL), elevated triglyceride (> 150 mg/dL), high waist circumference (≥ 80 cm), and prior diagnosis of diabetes or elevated fasting glucose level (≥ 100 mg/dL). Among 296 newly diagnosed BC cases and 259 healthy controls, multivariable logistic regression models were utilized to estimate adjusted odds ratios (aOR) and 95% confidence intervals (95% CI) for the association between MetS and BC overall. Multinomial logistic regression models were used to evaluate each molecular subtype (Luminal A, Luminal B, HER2-enriched and triple-negative or TNBC). Results: After adjusting for age, socio-demographic and reproductive risk factors, there was a positive association between MetS and BC (aOR: 1.84, 95% CI: 1.07, 3.16). In stratified analyses, MetS was associated with BC regardless of BMI status; however, the estimate was significant only among normal weight women (aOR: 3.85; 95% CI: 1.25, 11.90). MetS was significantly associated with TNBC subtype (aOR: 4.37, 95% CI: 1.67, 11.44); associations for other molecular subtypes were not statistically significant. Conclusion: MetS appears to be a robust risk factor for BC, particularly for TNBC. Public health and clinical interventions can provide substantial benefits in reducing the burden of MetS and preventing BC among Nigerian women.

KW - Cholesterol

KW - Diabetes

KW - Hypertension

KW - Nigeria

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85122101324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122101324&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2021.11.004

DO - 10.1016/j.clbc.2021.11.004

M3 - Article

AN - SCOPUS:85122101324

SN - 1526-8209

VL - 22

SP - e463-e472

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

IS - 4

ER -

Metabolic Syndrome and Risk of Breast Cancer by Molecular Subtype: Analysis of the MEND Study

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this